Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in F...(766 $23301 Non-GAAP Net Income .....),Health

Non-GAAP Net Income

GAAP Net Income $13,793 $19,784

Restructuring Costs 2,384 586

Baxter PI Settlement (5,700)

Tax benefit associated with Restructuring Costs (847) (176)

Tax benefit associated with Baxter PI Settlement 1,721

Resolution of Tax Contingencies (399)

Non-GAAP NET INCOME $15,330 $15,816

Non-GAAP Net Income per common

share assuming dilution

GAAP Net Income per common share assuming

dilution $0.52 $0.72

Restructuring Costs after tax per common share

assuming dilution $0.06 $0.02

Baxter PI Settlement per common share assuming

dilution $0.00 ($0.15)

Resolution of Tax Contingencies per common share

assuming dilution $0.00 ($0.01)

Non-GAAP Net Income per common share assuming

dilution $0.58 $0.58

Reconciliation of Non-GAAP Measures for the Full Year FY08 and FY07

03/29/08 03/31/07

Non-GAAP S,G&A

GAAP S,G&A $163,116 $137,073

Restructuring Costs (6,307) (3,518)

Non-GAAP S,G&A $156,809 $133,555

Non-GAAP Operating expenses

GAAP Operating Expenses $187,438 $164,555

Restructuring Costs (6,307) (3,518)

In-Process Research and Development
'/>"/>